ALLO News

The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or below issue. One small SPAC priced. Anaplan priced $2 above the range and popped 43% on Friday,...read more

Allogene Therapeutics, a Phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, raised $288 million by offering 16 million shares at $18, the high end of the range of $16 to $18. Allogene Therapeutics plans to list on the Nasdaq under the symbol ALLO. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as lead managers on the deal....read more

ThiS 5-IPO week is led by cloud-based business planning software provider Anaplan, which hopes to follow in the footsteps of the many other high-flying SaaS IPOs of 2018 (31% average return). Also pricing this week is Livent, which produces lithium compounds, a key component in electric vehicle batteries. There are two early-stage biotechs pricing this week, both founded in...read more

Allogene Therapeutics, a phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $272 million by offering 16 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Allogene Therapeutics would command a fully diluted market value of $2.1...read more